ERBB2 and gastric cancer: In a phase 1/2 dose escalation and dose expansion trial MEDI4276 was investigated in patients with advanced pretreated HER2 expressing (IHC 2+) breast or gastric cancer (clinicaltrials.gov identifier NCT02564900) [35].